Collegium Pharmaceutical, Inc.
COLL
$38.39
-$0.38-0.98%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 188.00M | 177.76M | 181.95M | 159.30M | 145.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 188.00M | 177.76M | 181.95M | 159.30M | 145.28M |
| Cost of Revenue | 22.19M | 21.48M | 24.22M | 20.41M | 19.96M |
| Gross Profit | 165.81M | 156.27M | 157.73M | 138.90M | 125.32M |
| SG&A Expenses | 72.70M | 76.42M | 58.65M | 42.07M | 40.28M |
| Depreciation & Amortization | 55.47M | 55.47M | 55.47M | 40.80M | 34.52M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 150.36M | 153.38M | 138.34M | 103.28M | 94.75M |
| Operating Income | 37.64M | 24.38M | 43.61M | 56.03M | 50.52M |
| Income Before Tax | 17.03M | 3.12M | 17.27M | 15.58M | 29.10M |
| Income Tax Expenses | 5.04M | 705.00K | 4.73M | 6.25M | 9.49M |
| Earnings from Continuing Operations | 11.98M | 2.42M | 12.54M | 9.34M | 19.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.98M | 2.42M | 12.54M | 9.34M | 19.61M |
| EBIT | 37.64M | 24.38M | 43.61M | 56.03M | 50.52M |
| EBITDA | 94.24M | 80.94M | 100.12M | 97.77M | 85.99M |
| EPS Basic | 0.38 | 0.08 | 0.39 | 0.29 | 0.60 |
| Normalized Basic EPS | 0.38 | 0.11 | 0.44 | 0.79 | 0.76 |
| EPS Diluted | 0.34 | 0.07 | 0.35 | 0.27 | 0.52 |
| Normalized Diluted EPS | 0.31 | 0.11 | 0.35 | 0.64 | 0.61 |
| Average Basic Shares Outstanding | 31.81M | 31.79M | 32.08M | 32.26M | 32.43M |
| Average Diluted Shares Outstanding | 39.08M | 32.84M | 40.11M | 40.16M | 40.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |